Exact Sciences (EXAS) Likely to Benefit From USPTF Colorectal Screening Guideline Expansion - Craig-Hallum
Tweet Send to a Friend
Craig-Hallum analyst Alexander Nowak reiterated a Buy rating and $144.00 price target on Exact Sciences (NASDAQ: EXAS) after the USPSTF ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
